Summary. Most lateral flow assay development projects do not fail because the core science is wrong. They fail because the development process did not remove the right risks at the right time. Teams too often move into development and optimization before establishing a de-risked, mature feasibility assessment, use a reagent set that was never characterized in the target matrix, or execute design transfer too early in the program.
This article explains how lateral flow assay development works, what happens at each phase, and what technical and business teams should expect when evaluating a CDMO partner for rapid test and diagnostics programs.
Table of Content
What Is a Lateral Flow Assay Development and Why Does It Matter?
A lateral flow assay is a rapid test, often 5–10 minutes, designed for fast analyte detection in a simple format. Most lateral flow assays are single-step and widely used in point-of-care settings because they can provide qualitative or quantitative results at home or in a doctor’s office.
A familiar example is the pregnancy test, which detects human chorionic gonadotropin. That same core platform can be modified for other applications, including health screening, infectious disease testing, environmental monitoring, food safety, and drug-of-abuse testing. Lateral flow tests can detect a variety of biomarkers across different sample types: urine, whole blood, plasma, saliva, tear fluid, and stool.
There are six distinct phases in the lateral flow assay development process. Understanding which phase your product is in and what comes next matters not only from a scientific perspective but also from business management and financial perspectives. The six phases are:
1. Concept Design
2. Feasibility Assessment
3. Assay Optimization
4. Verification of Assay Performance
5. Verification for Point-Of-Care and Rapid Diagnostic Use
6. Design Transfer and Manufacturing Scale Up
Phase 1: Concept Design
The most crucial step in any assay development program is first defining the conceptual design of the assay. Concept design is driven by design inputs, which serve as the blueprint for the assay and the backbone of the entire development process.
Design inputs answer the who, what, when, and why of the test. Who are the intended users? What will the product look like, and what will it detect? When will it be performed? And why would someone use this test over existing alternatives?
A Product Requirements Document is the standard output of this step. Common design input requirements for lateral flow assays include:
• What is the target biomarker or biomarkers?
• What is the target limit of detection?
• Is this a qualitative or quantitative assay?
• Are commercially available reagents available for purchase?
• What sample matrix is the biomarker found in?
• Will the test be used in a clinic or at home by patients?
• What regulatory pathway applies?
An experienced assay developer will ask for these inputs at the outset and help the client define them based on prior program experience. Design inputs established in the first few weeks set the performance ceiling for everything downstream. Once these criteria are defined, Phase 2: Feasibility Assessment can begin.
An experienced assay developer will ask for these inputs at the outset and help the client define them based on prior program experience. Design inputs established in the first few weeks set the performance ceiling for everything downstream. Once these criteria are defined, Phase 2: Feasibility Assessment can begin.
Phase 2: Feasibility Assessment
Once concept design and design inputs are established, the feasibility assessment begins. The most important decision in this phase is reagent selection. The difference between a successful and a failed assay development program often comes down to whether the right reagents were identified and characterized before development began.
The first question is whether commercial reagents are available for purchase or whether this is a novel assay with limited commercially available options. If commercial reagents exist, a list should be generated, ordered, and screened. If no commercial reagents are available, a reagent development program must be initiated before the feasibility assessment can proceed.
Once the reagent pathway is established, antibody pair matching begins. Assay developers screen a matrix of reagents and antibodies in a buffer system. Each antibody is conjugated to nanoparticles to serve as the detection reagent and striped onto a nitrocellulose membrane to serve as the capture reagent. Every antibody is tested in both roles.
Buffer screening runs in parallel: various buffer chemicals are tested across different pH values, ionic strength, and salt content. A surfactant screen should also be performed to evaluate various surfactants and concentrations. Nitrocellulose membranes, sample pads, and absorbent pad screens are recommended but can be deferred to Phase 3 if needed.
Reagent selection should be driven by the design inputs established in Phase 1, specifically the limit of detection. Any nonspecific binding should be addressed through buffer optimization or additional reagent screening.
If multiple biomarkers are being targeted, establishing feasibility in singleplex before attempting multiplex development is strongly recommended. Each antibody pair may require its own combination of buffers, surfactants, salts, and proteins to function optimally. Singleplex feasibility informs multiplexing strategies in Phase 3.
To exit feasibility successfully, a visible signal at or below the target limit of detection, with little to no nonspecific binding, should be apparent. A good feasibility assessment produces a clear go-or-no-go decision, a proposed assay design, an early reagent plan, and a realistic risk assessment.
Teams that skip a thorough feasibility assessment often spend months optimizing a concept that was never technically sound enough to support a viable lateral flow program.
Phase 3: Assay Optimization
Assay optimization is where lateral flow test development becomes disciplined engineering rather than exploratory science.
Work completed during Phase 2 is typically performed in a buffer. An antibody that performs well in buffer may perform poorly in urine, blood, or other sample matrices. At this phase, the team applies lessons from the feasibility phase and begins work on the targeted sample matrix. Early work can be done using contrived samples, where purified antigen is spiked into the native target matrix.
Nitrocellulose membranes are screened in this phase. There are a variety of membrane manufacturers, speeds, and pore sizes to choose from. It is recommended to screen multiple vendors and pore sizes, as the membrane controls flow characteristics, signal formation, and background. A faster membrane can reduce assay run time but may result in lower sensitivity. A slower membrane may improve signal intensity but increase background or nonspecific binding and lengthen the time to result.
Sample pads condition the sample before it reaches the critical detection and capture reagents. Selecting the appropriate sample pad is critical and depends on the target sample matrix.
For whole blood, specialty sample pads must be used to retain red blood cells and separate out plasma without significant hemolysis. For saliva, a viscous sample, mechanical filtration helps remove mucins and other salivary contaminants before they reach the conjugate, thereby reducing conjugate aggregation. Sample pad material type and thickness can also influence filtration, assay speed, sensitivity, and required sample volume.
Assay chemistry and stability work continue in parallel. Investigation into blocking agents, surfactants, salts, and other formulation changes addresses nonspecific binding, specificity, long-term shelf life, and overall assay performance.
If the assay is intended to be multiplexed, the individual singleplex assays must be combined, and multiplex optimization performed. If the assay output is quantitative, a lateral flow reader — phone-based, bespoke, or benchtop — will be needed to capture quantitative data.
The assay must also be integrated into a cassette or plastic housing. Once optimized for contrived samples, real clinical samples must be tested to validate the final assay design.
At the end of Phase 3, the lateral flow assay must work with all design inputs met, and all testable and verifiable outputs must be measurable.
Stage 4: Verification of Assay Performance
Verification and validation are the critical evaluations that confirm a test performs reliably, accurately, and consistently. Although the terms are often used interchangeably, they answer different questions and serve distinct purposes in the development process.
Verification asks: “Did we build the assay right?” It confirms that the assay meets technical specifications — detection limit, precision, and cross-reactivity — within the design criteria defined during Phase 1. Key analytical performance characteristics evaluated at this stage include precision, accuracy, sensitivity, specificity, linearity, and reproducibility.
Validation asks: “Did we build the right assay for its intended use?” It is a more comprehensive process that establishes documented evidence that the test is fit for purpose. Systematic assessment of the limit of detection, analytical sensitivity, analytical specificity, precision, accuracy, robustness, and user performance is evaluated.
Both are required. Neither replaces the other. Together, verification and validation ensure the developed product will deliver trustworthy performance.
Stage 5: Verification for Point-Of-Care and Rapid Diagnostic Use
For lateral flow assays intended for point-of-care or home use, the assay must demonstrate performance under conditions beyond controlled laboratory settings. This phase evaluates robustness under real-world variables: user error, environmental variation, and handling conditions that a controlled development environment cannot replicate.
Whole blood, urine, saliva, and swab extracts do not behave the same way across care settings. This phase removes the risk that an assay works only in development and not in the environment where it will actually be used.
Regulatory pathway requirements are confirmed and addressed in this phase. For products seeking CLIA waiver status, the assay must meet specific performance criteria that reflect use in home or low-complexity settings. For products headed toward FDA 510(k), De Novo, or EU IVDR submission, the evidence package generated during Phase 4 is reviewed against submission requirements, and any gaps are identified and resolved before design transfer.
Usability and human factors studies may also be conducted at this phase, particularly for tests intended for lay users. Labeling and instructions for use are drafted and reviewed against regulatory expectations.
Stage 6: Design Transfer and Manufacturing Scale-Up
One reason a client may prefer a CDMO lateral flow partner over a development-only organization is the ability to carry the assay through design transfer and contract manufacturing scale-up within a single system.
Design transfer is not a late-stage administrative step. It is one of the most technically demanding parts of the program and one of the most common failure points in LFA development. When development is handed off to a separate manufacturing organization, undocumented development variables surface during scale-up — reagent ratios, process timing, environmental conditions — that were never formally recorded because they were assumed to be understood.
An in-house development team that works directly with the manufacturing division eliminates this boundary. Development staff serves as a technical resource during transfer, while the manufacturing team draws on process experience to guide scale-up from small-batch production to volumes that match the client’s forecasted needs. A process that works at a small scale may not translate directly to a larger scale without adjustments, and in-house continuity is the most reliable way to quickly catch and resolve those issues.
This phase produces the manufacturing process documentation, batch records, and quality system records required to support commercial production under ISO 13485 or an equivalent quality management system.
Common Reasons Lateral Flow Development Projects Stall
Most stalled projects follow a familiar pattern. Understanding these failure modes is useful whether you are starting a new program or troubleshooting one that has lost momentum.
No defined performance targets. If sensitivity, specificity, matrix, runtime, use setting, and user type are not agreed on early, development becomes guesswork. Every phase gate requires objective criteria to function.
Poor reagent strategy. Teams often begin with an antibody or antigen set that has not been characterized in the real matrix. The result is early optimism followed by lengthy troubleshooting cycles when the assay encounters blood, urine, or other complex samples.
Skipping feasibility. Teams jump into optimization to gain momentum before confirming compatibility among the assay format, reagent system, and target analyte. That leads to expensive development cycles with very little real progress.
Treating design transfer as a late-stage task. By then, undocumented variables are built into the assay. Scale-up reveals that the development process depended on conditions that no one properly recorded.
Underestimating robustness requirements. For rapid diagnostic tests intended for CLIA-waived or field use, the assay must tolerate user error, variable environments, and real-world handling. That requirement must be built into the assay design from the beginning, not added at the end.
What to Look for in an LFA Development Partner
When evaluating a lateral flow assay development partner, ask how they work, not just what credentials they list. The most important questions concern process, quality systems, transfer capability, and experience under conditions similar to yours.
Do they operate under a documented quality management system such as ISO 13485, or one aligned with it?
ISO 13485 is the quality management standard for medical device organizations. It affects how design inputs are documented, how changes are controlled, how investigations are handled, and how development records are maintained. That matters because the data package created during development must support verification, validation, manufacturing transfer, and future regulatory decisions.
Do they develop and manufacture in-house, or do they hand the assay to a separate organization after feasibility, optimization, or verification?
That boundary is one of the most common failure points in LFA programs. A partner that handles both development and manufacture within a single system can usually reduce transfer risk and manage scale-up more effectively.
Can they walk you through their phase-gate process and show you the actual deliverables at each phase?
Ask to see examples of feasibility reports, optimization plans, verification protocols, validation plans, and transfer documentation. A strong partner should be able to show how the process works in practice, not just describe it at a high level.
Have they worked in your target matrix and intended use environment?
Whole blood is different from urine. Field deployment is different from controlled clinical use. Experience in the right context affects the speed of development, first-pass success, and the quality of early technical decisions.
FAQ About Lateral Flow Assay Development
How long does lateral flow assay development take?
A complete lateral flow assay development program — from feasibility through design transfer — typically takes 12 to 24 months, depending on assay complexity, the availability of characterized antibodies, and the regulatory pathway. Feasibility and optimization together commonly run 4 to 8 months. Verification and validation add another 4 to 10 months. Design transfer and manufacturing scale-up typically take 2 to 4 months. Programs with well-characterized binders and clearly defined performance targets consistently run faster than those where reagent sourcing or target specifications must be resolved mid-project.
What do I need before starting lateral flow test development?
You need a defined target analyte, intended use, target matrix, and clear performance goals. Any existing antibody data, materials, or early feasibility data will help reduce technical risk. If you do not yet have characterized antibodies, that is a solvable problem, but it needs to be factored into the project timeline from the start.
What is the difference between verification and validation?
Verification confirms that the assay meets the technical specifications for detection limit, precision, and cross-reactivity. Validation confirms that the assay works for the user and the use environment for which it was designed. Both are required, and neither replaces the other. For a full overview, see Palladium’s resource on verification vs. validation.
What is the difference between a CRO and a CDMO for LFA development?
A CRO may help generate data, but it is not structured to carry the assay through manufacturing transfer. A CDMO lateral flow partner supports both development and manufacturing, reducing the risk of failure during handoff. That distinction becomes most consequential at the design transfer phase, when undocumented development variables surface during scale-up.
At what stage should we engage a CDMO partner?
Earlier than most teams expect. The highest-value intervention point is before feasibility, not after optimization. Design input definition, reagent strategy, and matrix choices made in the first few weeks set the performance ceiling for everything downstream. Engaging a CDMO at the concept stage means those decisions are made with manufacturing and regulatory context built in, not retrofitted later.
What happens if my antibodies have not been characterized in my target matrix?
It is one of the most common causes of stalled development programs. An antibody that performs well in buffer can behave very differently in whole blood, urine, or a complex swab extract — reduced affinity, increased nonspecific binding, or outright failure at the test line. The right approach is to treat matrix characterization as part of feasibility, not optimization. If you are starting with off-the-shelf antibodies or early research-grade material, a structured feasibility study can identify gaps before committing development resources.
Do I need ISO 13485 certification to begin a project?
Not every early-stage program begins inside a certified system, but a regulated product should be developed with quality documentation in mind from the start. That becomes increasingly important as the program approaches verification, validation, and manufacturing readiness. What matters most is that your development partner operates under a QMS that produces documentation compatible with your eventual regulatory submissions.
Ready to Discuss Your Project?
Palladium Diagnostics works with a focused number of rapid diagnostic and lateral flow assay development programs at a time. If you are evaluating a new project and want a practical view of feasibility, development phases, and scale-up risk, the best next step is a 30-minute feasibility conversation.
